Log In
Print
BCIQ
Print
Print this Print this
 

delamanid (Deltyba) (OPC-67683)

  Manage Alerts
Collapse Summary General Information
Company Otsuka Pharmaceutical Co. Ltd.
DescriptionNitro-dihydro-imidazooxazole derivative
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationTuberculosis
Indication DetailsTreat multidrug-resistant tuberculosis (MDR-TB) infection; Treat pulmonary multidrug-resistant tuberculosis (MDR-TB) in adults when alternative treatments cannot be used due to resistance or intolerance; Treat tuberculosis (TB) infection
Regulatory Designation

EU - Conditional Approval (Treat pulmonary multidrug-resistant tuberculosis (MDR-TB) in adults when alternative treatments cannot be used due to resistance or intolerance);
EU - Orphan Drug (Treat multidrug-resistant tuberculosis (MDR-TB) infection);
EU - Standard Review (Treat multidrug-resistant tuberculosis (MDR-TB) infection);
Japan - Orphan Drug (Treat multidrug-resistant tuberculosis (MDR-TB) infection);
Japan - Standard Review (Treat multidrug-resistant tuberculosis (MDR-TB) infection)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today